01 July 2016

A million for hemophilia gene therapy

The British investment fund UCL Technology Fund will invest 1 million pounds (1.3 million euros) in the biopharmaceutical company Freeline Therapeutics, according to the European Pharmaceutical Review (UCL Technology Fund invests 1m pounds in gene therapy company, Freeline).

Freeline develops and commercializes gene therapy for the treatment of blood diseases, in particular, hemophilia. The company was founded in December 2015 by the British Syncona Foundation and the UCL Business technology transfer company of University College London.

The main product in the development of Freeline is gene therapy based on adenoassociated virus. The drug has already successfully passed the first stage of clinical trials involving 10 patients suffering from type B hemophilia.

Portal "Eternal Youth" http://vechnayamolodost.ru  01.07.2016

Found a typo? Select it and press ctrl + enter Print version